# Artelo Biosciences announces 6-for-1 reverse stock split

SOLANA BEACH, Calif. - Artelo Biosciences, Inc. (NASDAQ:ARTL), a micro-cap pharmaceutical company currently valued at $3.71 million, will implement a 6-for-1 reverse stock split effective June 13, 2025, the clinical-stage pharmaceutical company announced Wednesday. According to InvestingPro data, the stock currently trades at $1.13.

The company’s board of directors approved the reverse split on May 20 to increase the per-share price and meet Nasdaq’s minimum $1.00 per share closing bid price requirement for continued listing. While the stock has shown strong returns over the past three months, its current ratio of 0.49 indicates potential liquidity challenges.

Following the split, Artelo’s common stock will trade on the Nasdaq Capital Market under the same ticker symbol but with a new CUSIP number: 04301G607.

The reverse split will automatically convert every six shares of issued and outstanding common stock into one share. Shareholders’ proportional ownership percentages will remain unchanged, and no action is required from shareholders. All outstanding warrants and derivatives will automatically adjust according to their terms.

After the split takes effect, Artelo will have approximately 546,667 shares of common stock outstanding.

Artelo Biosciences focuses on developing therapeutics that modulate lipid-signaling pathways for conditions including anorexia, cancer, anxiety, dermatological conditions, pain, and inflammation.

The information in this article is based on a press release statement from the company.

In other recent news, Artelo Biosciences presented promising data at the British Pain Conference regarding its Fatty Acid Binding Protein (FABP) inhibitors for treating osteoarthritis (OA) pain. The study highlighted ART26.12, Artelo’s lead FABP5 inhibitor, which demonstrated analgesic and anti-nociceptive effects in various pain models, including a surgical rat model of OA. The results showed that ART26.12 improved the rats’ ability to bear weight on an OA-affected limb for up to four weeks, with its effects being comparable to naproxen but with fewer side effects when used chronically. ART26.12 is a novel, non-opioid, non-steroidal drug candidate initially developed for preventing and treating peripheral neuropathy caused by chemotherapy, now showing potential as an alternative treatment for chronic OA pain. The first Phase 1 trial results for ART26.12 are anticipated in the second quarter of 2025, focusing initially on chemotherapy-induced peripheral neuropathy. Artelo Biosciences is advancing its portfolio, which includes small molecule inhibitors of FABPs with therapeutic potential for various conditions, including certain cancers and neuropathic pain. The company’s recent presentation underscores its dedication to developing therapeutics that address unmet medical needs.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.